ArticleHormone research in paediatrics2026
Failure to Thrive in Infants with Prader-Willi Syndrome and Long-Term Effects of GH Treatment on FTT.
Article in Hormone research in paediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionFailure to thrive (FTT) with feeding difficulties and hypotonia are well-known features in infants with Prader-Willi syndrome (PWS). Limited studies reported the percentage of infants with FTT and it is unknown whether growth hormone (GH) treatment affects body composition of infants with or without FTT differently. Aims of the study were to evaluate the percentage of infants with PWS with FTT from birth to age 6 months and to investigate the 5-year GH effects on body composition in infants with or without FTT at GH start.
methodsWe defined FTT as weight-for-length <-2 SDS and evaluated the percentage of infants with FTT in a group of 54 infants from birth to age 6 months. In addition, we investigated in 166 children the 5-year GH effects on body composition, comparing children with and without FTT at GH start. All infants were treated with 1.0 mg GH/m2/day (∼0.035 mg/kg/day). Body composition was determined by dual-energy X-ray absorptiometry.
resultsFrom birth to age 6 months, 29% of infants had FTT at 1 month, 20% at 3 months, and 16% at 6 months. At GH start, at a median age of 1.03 (IQR 0.45, 1.89) years, 12% (20/166) had FTT (FTT
conclusionsTwenty-nine percent of infants had FTT at 1 month, 20% at 3 months, and 16% at 6 months. Twelve percent had FTT at the start of GH treatment. Children with FTT at GH start showed greatest LBM improvement during GH treatment, resulting in a similar LBM after 5 years of GH treatment as those without FTT at GH start.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.